10:51 AM EDT, 06/24/2024 (MT Newswires) -- CytoSorbents ( CTSO ) said Monday it has received the Taiwan Food and Drug Administration's authorization for its blood purification device CytoSorb.

The approved uses include treating conditions like cytokine storm, sepsis, liver disease, and trauma, as well as removing antithrombotic drugs like Brilinta and Xarelto during cardiac surgery to reduce bleeding risks, the company said.

CytoSorb devices are already approved in the EU and used in 75 countries, according to the company.

Price: 0.77, Change: -0.04, Percent Change: -4.38